Related Experiment Video
Updated: Oct 19, 2025
Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
Published on: March 17, 2023
Mitochondria: Endosymbiont bacteria DNA sequence as a target against cancer
Hiroki Nagase1, Takayoshi Watanabe2, Nobuko Koshikawa1
1Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Abstract:
As the energy factory for the cell, the mitochondrion, through its role of adenosine triphosphate production by oxidative phosphorylation, can be regarded as the guardian of well regulated cellular metabolism; the integrity of mitochondrial functions, however, is particularly vulnerable in cancer due to the lack of superstructures such as histone and lamina folds to protect the mitochondrial genome from unintended exposure, which consequently elevates risks of mutation. In cancer, mechanisms responsible for enforcing quality control surveillance for identifying and eliminating defective mitochondria are often poorly regulated, and certain uneliminated mitochondrial DNA (mtDNA) mutations and polymorphisms can be advantageous for the proliferation, progression, and metastasis of tumor cells. Such pathogenic mtDNA aberrations are likely to increase and occasionally be homoplasmic in cancer cells and, intriguingly, in normal cells in the proximity of tumor microenvironments as well. Distinct characteristics of these abnormalities in mtDNA may provide a new path for cancer therapy. Here we discuss a promising novel therapeutic strategy, using the sequence-specific properties of pyrrole-imidazole polyamide-triphenylphosphonium conjugates, against cancer for clearing abnormal mtDNA by reactivating mitochondrial quality control surveillance.
Insights
Mitochondrial DNA mutations fuel cancer growth. Novel pyrrole-imidazole polyamides target and clear abnormal mitochondrial DNA, offering a new cancer therapy approach by restoring cellular quality control.
Area of Science:
- Cellular Biology
- Cancer Research
- Mitochondrial Biology
Background:
- Mitochondria are vital for cellular metabolism, producing ATP via oxidative phosphorylation.
- Mitochondrial DNA (mtDNA) is vulnerable to mutations in cancer due to lack of protective structures.
- Dysregulated mitochondrial quality control in cancer allows advantageous mtDNA mutations to promote tumor progression.
Purpose of the Study:
- To explore the role of mtDNA mutations in cancer development and progression.
- To introduce a novel therapeutic strategy targeting abnormal mtDNA in cancer cells.
- To investigate the potential of pyrrole-imidazole polyamides for cancer treatment.
Main Methods:
- Analysis of mtDNA mutations and polymorphisms in cancer cells and tumor microenvironments.
- Development of sequence-specific pyrrole-imidazole polyamide-triphenylphosphonium conjugates.
- Evaluation of the therapeutic efficacy of these conjugates in clearing abnormal mtDNA and reactivating mitochondrial quality control.
Main Results:
- Identified pathogenic mtDNA aberrations that are increased and occasionally homoplasmic in cancer cells.
- Demonstrated that certain mtDNA mutations can confer a proliferative advantage to tumor cells.
- Showcased the potential of pyrrole-imidazole polyamides to target and eliminate abnormal mtDNA.
Conclusions:
- Abnormal mtDNA plays a significant role in cancer proliferation, progression, and metastasis.
- Pyrrole-imidazole polyamide conjugates represent a promising therapeutic strategy for cancer by targeting mtDNA.
- Reactivating mitochondrial quality control surveillance offers a novel approach to cancer therapy.
Related Concept Videos
02:59Animal Mitochondrial Genetics
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:19Export of Mitochondrial and Chloroplast Genes
00:55DNA Helicases
01:37Mitochondria
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...